Literature DB >> 1706219

Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.

C V Catapano1, K B Chandler, D J Fernandes.   

Abstract

The effects of fludarabine triphosphate (Fara-ATP), 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP), and aphidicolin on primer RNA and DNA synthesis in human CCRF-CEM leukemia cells were investigated. RNA-primed Okazaki fragment synthesis was monitored by first incubating whole cell lysates for 10 min in the presence or absence of the compound and then following the incorporation of [alpha-32P]ATP and [3H]dTTP into the primer RNA and DNA portions, respectively, of the Okazaki fragments. In whole cell lysates the degree of DNA synthesis inhibition induced by Fara-ATP was directly related to the extent of primer RNA synthesis inhibition over the entire range of Fara-ATP concentrations tested (10-50 microM). In contrast, primer RNA formation was stimulated by concentrations of ara-CTP (25-200 microM) and aphidicolin (0.5-5 micrograms/ml) that inhibited DNA synthesis. The primer RNA recovered from cell lysates incubated with either Fara-ATP, ara-CTP, or aphidicolin was of normal length, predominately 11 nucleotides. Fara-ATP was a more potent inhibitor of the polydeoxythymidylate primase activity than of the DNA polymerase alpha/delta activities present in the 100,000 x g supernatants of CCRF-CEM cells. Fara-ATP was a noncompetitive inhibitor of DNA primase with respect to ATP [50% inhibitory concentration, 2.3 +/- 0.3 (SD) microM, Ki = 6.1 +/- 0.3 (SE) microM] and the Km(ATP)/Ki (Fara-ATP) was 25. The 50% inhibitory concentration values of Fara-ATP for DNA polymerases alpha/delta activities on calf thymus DNA were 43 +/- 1.6 (SD) microM and greater than 100 microM with respect to dATP and dTTP. The effects of ara-CTP and aphidicolin on these enzymes were opposite those seen with Fara-ATP, since 50% inhibitory concentrations of either ara-CTP or aphidicolin for DNA polymerases alpha/delta did not inhibit polydeoxythymidylate primase activity. The results provide evidence that fludarabine phosphate blocks DNA synthesis in CCRF-CEM cells through inhibition of primer RNA formation. In contrast, the accumulation of primer RNA and RNA-primed Okazaki fragments that is induced by ara-CTP and aphidicolin could lead to the rereplication and amplification of chromosomal DNA segments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706219

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

2.  RNA Targeting in Acute Myeloid Leukemia.

Authors:  Alessandra Messikommer; Katja Seipel; Stephen Byrne; Peter J M Valk; Thomas Pabst; Nathan W Luedtke
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-12

Review 3.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

Authors:  Amal A El-Mabhouh; Mary L Ayres; Elizabeth J Shpall; Veerabhadran Baladandayuthapani; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

5.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.

Authors:  L E Robertson; A W Denny; Y O Huh; W Plunkett; M J Keating; J A Nelson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 6.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

Review 7.  Structures to complement the archaeo-eukaryotic primases catalytic cycle description: What's next?

Authors:  Julien Boudet; Jean-Christophe Devillier; Frédéric H-T Allain; Georg Lipps
Journal:  Comput Struct Biotechnol J       Date:  2015-05-02       Impact factor: 7.271

8.  Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine.

Authors:  Sandro Holzer; Neil J Rzechorzek; Isobel R Short; Michael Jenkyn-Bedford; Luca Pellegrini; Mairi L Kilkenny
Journal:  ACS Chem Biol       Date:  2019-09-11       Impact factor: 5.100

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.